Vanda Pharmaceuticals Reports Strong Q1 Growth and Pipeline Progress, Entering New Growth Phase
Vanda Pharmaceuticals Inc. has reported a strong first quarter in 2025, driven by commercial success with Fanapt and promising pipeline developments, positioning the company for continued growth and future success.
3 minutes to read